MA27080A1 - Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant - Google Patents
Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenantInfo
- Publication number
- MA27080A1 MA27080A1 MA27659A MA27659A MA27080A1 MA 27080 A1 MA27080 A1 MA 27080A1 MA 27659 A MA27659 A MA 27659A MA 27659 A MA27659 A MA 27659A MA 27080 A1 MA27080 A1 MA 27080A1
- Authority
- MA
- Morocco
- Prior art keywords
- same
- rimonabant
- preparing
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0114579A FR2831883B1 (fr) | 2001-11-08 | 2001-11-08 | Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27080A1 true MA27080A1 (fr) | 2004-12-20 |
Family
ID=8869285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA27659A MA27080A1 (fr) | 2001-11-08 | 2004-04-28 | Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
Country Status (33)
Country | Link |
---|---|
US (2) | US20050043356A1 (fr) |
EP (1) | EP1446384A1 (fr) |
JP (2) | JP4181994B2 (fr) |
KR (2) | KR20090089485A (fr) |
CN (1) | CN100412063C (fr) |
AP (1) | AP1830A (fr) |
AR (1) | AR037253A1 (fr) |
AU (1) | AU2002350869B2 (fr) |
BR (1) | BR0213931A (fr) |
CA (1) | CA2464145A1 (fr) |
CO (1) | CO5580827A2 (fr) |
CR (1) | CR7333A (fr) |
EA (1) | EA006771B1 (fr) |
EC (1) | ECSP045088A (fr) |
FR (1) | FR2831883B1 (fr) |
GE (1) | GEP20063894B (fr) |
HR (1) | HRP20040403A2 (fr) |
HU (1) | HUP0402043A3 (fr) |
IL (2) | IL161533A0 (fr) |
IS (1) | IS7226A (fr) |
MA (1) | MA27080A1 (fr) |
ME (1) | MEP21908A (fr) |
MX (1) | MXPA04004394A (fr) |
NO (1) | NO326648B1 (fr) |
NZ (1) | NZ532369A (fr) |
OA (1) | OA12721A (fr) |
PL (1) | PL369372A1 (fr) |
RS (1) | RS36904A (fr) |
TN (1) | TNSN04079A1 (fr) |
TW (1) | TW200302824A (fr) |
UA (1) | UA76776C2 (fr) |
WO (1) | WO2003040105A1 (fr) |
ZA (1) | ZA200402999B (fr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2831883B1 (fr) * | 2001-11-08 | 2004-07-23 | Sanofi Synthelabo | Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
IN2008CN05409A (fr) | 2002-07-18 | 2015-10-02 | Cytos Biotechnology Ag | |
FR2861992B1 (fr) * | 2003-11-10 | 2007-07-20 | Sanofi Synthelabo | Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide. |
AU2006264649A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | GPCR agonists |
EP1816125A1 (fr) * | 2006-02-02 | 2007-08-08 | Ranbaxy Laboratories, Ltd. | Formes cristallines d'un antagoniste du récepteur cannabinoïde CB1 et son procédé de préparation |
FR2897060B1 (fr) * | 2006-02-08 | 2008-07-25 | Sanofi Aventis Sa | Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
AR061606A1 (es) * | 2006-06-22 | 2008-09-10 | Medichem Sa | Formas solidas de rimonabant y procesos para su preparacion |
WO2008044153A2 (fr) * | 2006-08-29 | 2008-04-17 | Medichem, S.A. | Procédé de synthèse amélioré de rimonabant |
EP2057144A4 (fr) * | 2006-09-01 | 2010-06-02 | Hetero Drugs Ltd | Nouveaux polymorphes de rimonabant |
WO2008032330A2 (fr) * | 2006-09-11 | 2008-03-20 | Hetero Drugs Limited | Procédé amélioré pour l'obtention de rimonabant |
WO2008035023A1 (fr) * | 2006-09-19 | 2008-03-27 | Cipla Limited | Formes polymorphes de rimonabant |
WO2008056377A2 (fr) * | 2006-11-06 | 2008-05-15 | Cadila Healthcare Limited | Nouvelles formes du rimonabant |
WO2008064615A2 (fr) * | 2006-12-01 | 2008-06-05 | Zentiva, A.S. | Formes cristallines et amorphes du rimonabant et procédés permettant d'obtenir ces formes |
CA2673177A1 (fr) * | 2006-12-18 | 2008-06-26 | 7Tm Pharma A/S | Modulateurs de recepteurs cb1 |
AR064735A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
AR064736A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr |
PL2114933T3 (pl) | 2007-01-04 | 2012-02-29 | Prosidion Ltd | Piperydyny jako agoniści GPCR |
GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
BRPI0806312A2 (pt) | 2007-01-04 | 2011-09-06 | Prosidion Ltd | agonistas cgpr piperidina |
EP1944297A1 (fr) * | 2007-01-09 | 2008-07-16 | Miklós Vértessy | Rimonabant solide et cristallin et procédés de préparation, ainsi que composition pharmaceutique correspondante |
WO2008088900A2 (fr) * | 2007-01-18 | 2008-07-24 | Teva Pharmaceutical Industries Ltd. | Formes polymorphes d'une base de rimonabant et procédés pour leur préparation |
EP1953144A1 (fr) | 2007-01-30 | 2008-08-06 | Sandoz AG | Nouvelles formes polymorphes de N-pipéridino-5-(4-chlorophényl)-1-(2, 4-dichlorphényl)-4-méthyl-3-pyrazolecarboxamide |
FR2919862A1 (fr) * | 2007-08-06 | 2009-02-13 | Sanofi Aventis Sa | Le solvate de 3-methylbutan-1-ol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
FR2919867A1 (fr) * | 2007-08-06 | 2009-02-13 | Sanofi Aventis Sa | Le solvate de 2-methoxyethanol de rimonabant et son procede de preparation |
FR2919863A1 (fr) * | 2007-08-06 | 2009-02-13 | Sanofi Aventis Sa | Le solvate de n-methylpyrrolidone de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
FR2919864A1 (fr) * | 2007-08-06 | 2009-02-13 | Sanofi Aventis Sa | Le solvate de 1,4-dioxane de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
FR2919865A1 (fr) * | 2007-08-06 | 2009-02-13 | Sanofi Aventis Sa | Le solvate de dmso de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
WO2009153804A1 (fr) * | 2008-06-16 | 2009-12-23 | Cadila Healthcare Limited | Procédé de préparation de la forme 1 du rimonabant |
WO2010079241A1 (fr) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Utilisation d'antagonistes et/ou d'agonistes inverses des récepteurs cb1 pour la préparation de médicaments qui augmentent l'excitabilité des motoneurones |
FR3008620A1 (fr) * | 2013-07-22 | 2015-01-23 | Sanofi Sa | Formulation de comprime d'un inhibiteur de phosphatidylinositol 3-kinase |
WO2021075494A1 (fr) * | 2019-10-16 | 2021-04-22 | 大塚製薬株式会社 | Procédé de production de la centanafadine |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2713225B1 (fr) * | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
WO2003015700A2 (fr) * | 2001-08-15 | 2003-02-27 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogues du cannabinoide vasoconstricteurs |
FR2831883B1 (fr) * | 2001-11-08 | 2004-07-23 | Sanofi Synthelabo | Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
-
2001
- 2001-11-08 FR FR0114579A patent/FR2831883B1/fr not_active Expired - Fee Related
-
2002
- 2002-04-11 UA UA20040402974A patent/UA76776C2/uk unknown
- 2002-11-04 EA EA200400491A patent/EA006771B1/ru not_active IP Right Cessation
- 2002-11-04 RS YU36904A patent/RS36904A/sr unknown
- 2002-11-04 WO PCT/FR2002/003765 patent/WO2003040105A1/fr active Application Filing
- 2002-11-04 BR BR0213931-6A patent/BR0213931A/pt not_active IP Right Cessation
- 2002-11-04 JP JP2003542151A patent/JP4181994B2/ja not_active Expired - Fee Related
- 2002-11-04 ME MEP-219/08A patent/MEP21908A/xx unknown
- 2002-11-04 AU AU2002350869A patent/AU2002350869B2/en not_active Ceased
- 2002-11-04 IL IL16153302A patent/IL161533A0/xx unknown
- 2002-11-04 GE GE5606A patent/GEP20063894B/en unknown
- 2002-11-04 MX MXPA04004394A patent/MXPA04004394A/es unknown
- 2002-11-04 AP APAP/P/2004/003024A patent/AP1830A/en active
- 2002-11-04 KR KR1020097016373A patent/KR20090089485A/ko not_active Application Discontinuation
- 2002-11-04 HU HU0402043A patent/HUP0402043A3/hu unknown
- 2002-11-04 CA CA002464145A patent/CA2464145A1/fr not_active Abandoned
- 2002-11-04 CN CNB028219686A patent/CN100412063C/zh not_active Expired - Fee Related
- 2002-11-04 EP EP02785580A patent/EP1446384A1/fr not_active Withdrawn
- 2002-11-04 NZ NZ532369A patent/NZ532369A/en not_active IP Right Cessation
- 2002-11-04 US US10/494,211 patent/US20050043356A1/en not_active Abandoned
- 2002-11-04 PL PL02369372A patent/PL369372A1/xx not_active Application Discontinuation
- 2002-11-04 OA OA1200400131A patent/OA12721A/fr unknown
- 2002-11-04 KR KR1020047006969A patent/KR20050043774A/ko not_active Application Discontinuation
- 2002-11-06 AR ARP020104228A patent/AR037253A1/es unknown
- 2002-11-07 TW TW091132763A patent/TW200302824A/zh unknown
-
2004
- 2004-04-19 IS IS7226A patent/IS7226A/is unknown
- 2004-04-20 ZA ZA200402999A patent/ZA200402999B/en unknown
- 2004-04-20 IL IL161533A patent/IL161533A/en not_active IP Right Cessation
- 2004-04-27 EC EC2004005088A patent/ECSP045088A/es unknown
- 2004-04-28 MA MA27659A patent/MA27080A1/fr unknown
- 2004-05-04 CR CR7333A patent/CR7333A/es unknown
- 2004-05-04 CO CO04040840A patent/CO5580827A2/es not_active Application Discontinuation
- 2004-05-06 HR HR20040403A patent/HRP20040403A2/hr not_active Application Discontinuation
- 2004-05-07 TN TNP2004000079A patent/TNSN04079A1/fr unknown
- 2004-05-07 NO NO20041879A patent/NO326648B1/no not_active IP Right Cessation
-
2008
- 2008-07-11 JP JP2008181474A patent/JP4931874B2/ja not_active Expired - Fee Related
- 2008-10-28 US US12/259,701 patent/US20100190827A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27080A1 (fr) | Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant | |
MA28626B1 (fr) | Forme cristalline delta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
FR2891827B1 (fr) | Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
FR2882555B1 (fr) | Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
FR2882556B1 (fr) | Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
FR2882553B1 (fr) | Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
FR2882554B1 (fr) | Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
FR2816938B1 (fr) | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant | |
FR2827604B1 (fr) | Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant | |
IL163831A (en) | Derivatives of aminoindazoles, pharmaceutical compositions comprising them, process for their preparation and use thereof | |
FR2824825B1 (fr) | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
FR2822826B1 (fr) | Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
MA26740A1 (fr) | Derives de 13-methyl-erythromycine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
FR2794742B1 (fr) | Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant | |
PL393385A1 (pl) | Sposób modyfikacji i rekrystalizacji pokroju kryształów substancji leczniczej, kryształy mykofenolanu sodu i ich zastosowanie oraz kompozycja farmaceutyczna | |
HUP0401747A3 (en) | Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds | |
EE05242B1 (et) | 5-kloro-3-(4-metaansulfonlfenl)-6'-metl[2,3']bipridinli polmorfne vorm, selle valmistamismeetod, kasutamine ja farmatseutiline kompositsioon | |
FR2883876B1 (fr) | Derives d'indanyl-piperazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
FR2875807B1 (fr) | Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
FR2824828B1 (fr) | Nouveaux derives de piperidinecarboxamide, un procede pour leur preparation et les compositions pharmaceutiques les contenant | |
MA26678A1 (fr) | Forme polymorphe de monohydrate de zopolrestat, procedes pour sa preparation et compositions pharmaceutiques la contenant | |
FR2822153B1 (fr) | Nouveaux derives d'indenoindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
FR2791346B3 (fr) | Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant | |
FR2853649B1 (fr) | Nouveaux derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
FR2821843B1 (fr) | Nouveaux derives d'isoindoloindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |